Transmembrane phosphoinositide 3-phosphatase and tensin homolog (TPTE) (TPTE)

Transmembrane phosphoinositide 3-phosphatase and tensin homolog (TPTE) is a member of the PTEN phosphatase family characterized by its unique four-transmembrane domain structure, which anchors it to the plasma membrane (UniProt P56180). While it shares significant sequence homology with the tumor suppressor PTEN, TPTE expression is primarily restricted to the testis in healthy individuals, which classifies it as a cancer-testis antigen (PMID: 11030153). In the context of disease, TPTE is frequently overexpressed in various malignancies, including prostate, lung, and liver cancers, where it may contribute to altered phosphoinositide signaling (PMID: 15851453). Its enzymatic activity involves the dephosphorylation of phosphatidylinositol phosphates, potentially influencing the PI3K/Akt pathway, although its exact substrate specificity in vivo is still being elucidated (PMID: 10531343). As a result of its tumor-associated expression, TPTE is considered a potential target for cancer vaccines and other immunotherapies, as well as a candidate biomarker for diagnostic and prognostic applications in oncology (PMID: 21571334). While no drugs are currently approved for this target, its role as a tumor-specific antigen makes it a compelling candidate for precision oncology.

Other names

TPTECancer/testis antigen 44CT44PTEN2Transmembrane phosphoinositide 3-phosphatase and tensin homolog 1

The potential mechanism of action for therapeutic agents targeting TPTE includes the induction of antigen-specific T-cell responses against TPTE-expressing tumor cells or the inhibition of its lipid phosphatase activity to modulate oncogenic signaling (PMID: 21571334).